MESA LABORATORIES INC (MLAB) Fundamental Analysis & Valuation

NASDAQ:MLAB • US59064R1095

Current stock price

81.13 USD
-1.27 (-1.54%)
At close:
81.13 USD
0 (0%)
After Hours:

This MLAB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. MLAB Profitability Analysis

1.1 Basic Checks

  • MLAB had positive earnings in the past year.
  • MLAB had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: MLAB reported negative net income in multiple years.
  • In the past 5 years MLAB always reported a positive cash flow from operatings.
MLAB Yearly Net Income VS EBIT VS OCF VS FCFMLAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M

1.2 Ratios

  • The Return On Assets of MLAB (0.86%) is better than 66.07% of its industry peers.
  • With a decent Return On Equity value of 2.00%, MLAB is doing good in the industry, outperforming 67.86% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 3.58%, MLAB is in the better half of the industry, outperforming 64.29% of the companies in the same industry.
  • MLAB had an Average Return On Invested Capital over the past 3 years of 2.10%. This is significantly below the industry average of 12.34%.
  • The last Return On Invested Capital (3.58%) for MLAB is above the 3 year average (2.10%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 0.86%
ROE 2%
ROIC 3.58%
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
MLAB Yearly ROA, ROE, ROICMLAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • MLAB has a Profit Margin of 1.51%. This is in the better half of the industry: MLAB outperforms 66.07% of its industry peers.
  • MLAB has a Operating Margin of 6.96%. This is in the better half of the industry: MLAB outperforms 62.50% of its industry peers.
  • In the last couple of years the Operating Margin of MLAB has grown nicely.
  • The Gross Margin of MLAB (62.40%) is better than 80.36% of its industry peers.
  • MLAB's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 6.96%
PM (TTM) 1.51%
GM 62.4%
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
MLAB Yearly Profit, Operating, Gross MarginsMLAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

3

2. MLAB Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MLAB is destroying value.
  • MLAB has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, MLAB has more shares outstanding
  • The debt/assets ratio for MLAB has been reduced compared to a year ago.
MLAB Yearly Shares OutstandingMLAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M 5M
MLAB Yearly Total Debt VS Total AssetsMLAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of 1.36, we must say that MLAB is in the distress zone and has some risk of bankruptcy.
  • MLAB has a Altman-Z score (1.36) which is comparable to the rest of the industry.
  • The Debt to FCF ratio of MLAB is 4.41, which is a neutral value as it means it would take MLAB, 4.41 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of MLAB (4.41) is better than 73.21% of its industry peers.
  • MLAB has a Debt/Equity ratio of 0.86. This is a neutral value indicating MLAB is somewhat dependend on debt financing.
  • MLAB has a Debt to Equity ratio of 0.86. This is in the lower half of the industry: MLAB underperforms 78.57% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF 4.41
Altman-Z 1.36
ROIC/WACC0.34
WACC10.5%
MLAB Yearly LT Debt VS Equity VS FCFMLAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.3 Liquidity

  • MLAB has a Current Ratio of 1.94. This is a normal value and indicates that MLAB is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of MLAB (1.94) is worse than 64.29% of its industry peers.
  • MLAB has a Quick Ratio of 1.45. This is a normal value and indicates that MLAB is financially healthy and should not expect problems in meeting its short term obligations.
  • MLAB has a worse Quick ratio (1.45) than 67.86% of its industry peers.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.45
MLAB Yearly Current Assets VS Current LiabilitesMLAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

4

3. MLAB Growth Analysis

3.1 Past

  • MLAB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -87.40%.
  • The earnings per share for MLAB have been decreasing by -39.16% on average. This is quite bad
  • MLAB shows a small growth in Revenue. In the last year, the Revenue has grown by 4.12%.
  • The Revenue has been growing by 15.41% on average over the past years. This is quite good.
EPS 1Y (TTM)-87.4%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%351.94%
Revenue 1Y (TTM)4.12%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%3.64%

3.2 Future

  • MLAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 247.51% yearly.
  • MLAB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.11% yearly.
EPS Next Y3244.14%
EPS Next 2Y354.08%
EPS Next 3Y247.51%
EPS Next 5YN/A
Revenue Next Year4.19%
Revenue Next 2Y4.8%
Revenue Next 3Y4.11%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MLAB Yearly Revenue VS EstimatesMLAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M 250M
MLAB Yearly EPS VS EstimatesMLAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 2 3

6

4. MLAB Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 126.77, the valuation of MLAB can be described as expensive.
  • MLAB's Price/Earnings ratio is in line with the industry average.
  • The average S&P500 Price/Earnings ratio is at 25.50. MLAB is valued rather expensively when compared to this.
  • A Price/Forward Earnings ratio of 56.21 indicates a quite expensive valuation of MLAB.
  • Based on the Price/Forward Earnings ratio, MLAB is valued a bit cheaper than the industry average as 60.71% of the companies are valued more expensively.
  • MLAB's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.67.
Industry RankSector Rank
PE 126.77
Fwd PE 56.21
MLAB Price Earnings VS Forward Price EarningsMLAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MLAB indicates a rather cheap valuation: MLAB is cheaper than 82.14% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, MLAB is valued cheaper than 94.64% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.88
EV/EBITDA 14.01
MLAB Per share dataMLAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

  • MLAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of MLAB may justify a higher PE ratio.
  • A more expensive valuation may be justified as MLAB's earnings are expected to grow with 247.51% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y354.08%
EPS Next 3Y247.51%

4

5. MLAB Dividend Analysis

5.1 Amount

  • MLAB has a yearly dividend return of 0.78%, which is pretty low.
  • Compared to an average industry Dividend Yield of 0.12, MLAB pays a better dividend. On top of this MLAB pays more dividend than 96.43% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.89, MLAB's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.78%

5.2 History

  • The dividend of MLAB decreases each year by -0.50%.
  • MLAB has paid a dividend for at least 10 years, which is a reliable track record.
  • MLAB has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)-0.5%
Div Incr Years0
Div Non Decr Years21
MLAB Yearly Dividends per shareMLAB Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6

5.3 Sustainability

  • 93.97% of the earnings are spent on dividend by MLAB. This is not a sustainable payout ratio.
DP93.97%
EPS Next 2Y354.08%
EPS Next 3Y247.51%
MLAB Yearly Income VS Free CF VS DividendMLAB Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M -200M -250M
MLAB Dividend Payout.MLAB Dividend Payout, showing the Payout Ratio.MLAB Dividend Payout.PayoutRetained Earnings

MLAB Fundamentals: All Metrics, Ratios and Statistics

MESA LABORATORIES INC

NASDAQ:MLAB (3/24/2026, 8:00:00 PM)

After market: 81.13 0 (0%)

81.13

-1.27 (-1.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03
Earnings (Next)05-26
Inst Owners92.09%
Inst Owner Change-4%
Ins Owners5.44%
Ins Owner Change3.15%
Market Cap447.84M
Revenue(TTM)247.54M
Net Income(TTM)3.73M
Analysts80
Price Target106.59 (31.38%)
Short Float %4.49%
Short Ratio2.04
Dividend
Industry RankSector Rank
Dividend Yield 0.78%
Yearly Dividend0.64
Dividend Growth(5Y)-0.5%
DP93.97%
Div Incr Years0
Div Non Decr Years21
Ex-Date02-27
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)153.03%
Min EPS beat(2)130.33%
Max EPS beat(2)175.74%
EPS beat(4)3
Avg EPS beat(4)44.77%
Min EPS beat(4)-217.83%
Max EPS beat(4)175.74%
EPS beat(8)5
Avg EPS beat(8)420.17%
EPS beat(12)6
Avg EPS beat(12)229.7%
EPS beat(16)8
Avg EPS beat(16)172.52%
Revenue beat(2)1
Avg Revenue beat(2)-0.59%
Min Revenue beat(2)-1.95%
Max Revenue beat(2)0.77%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-3.63%
Max Revenue beat(4)0.77%
Revenue beat(8)4
Avg Revenue beat(8)0.47%
Revenue beat(12)4
Avg Revenue beat(12)-1.22%
Revenue beat(16)6
Avg Revenue beat(16)-1.01%
PT rev (1m)5.56%
PT rev (3m)10%
EPS NQ rev (1m)-10.53%
EPS NQ rev (3m)-3.77%
EPS NY rev (1m)19.12%
EPS NY rev (3m)19.12%
Revenue NQ rev (1m)0.55%
Revenue NQ rev (3m)1.07%
Revenue NY rev (1m)1.06%
Revenue NY rev (3m)1.06%
Valuation
Industry RankSector Rank
PE 126.77
Fwd PE 56.21
P/S 1.81
P/FCF 11.88
P/OCF 10.78
P/B 2.4
P/tB N/A
EV/EBITDA 14.01
EPS(TTM)0.64
EY0.79%
EPS(NY)1.44
Fwd EY1.78%
FCF(TTM)6.83
FCFY8.42%
OCF(TTM)7.52
OCFY9.27%
SpS44.84
BVpS33.82
TBVpS-16.71
PEG (NY)0.04
PEG (5Y)N/A
Graham Number22.07
Profitability
Industry RankSector Rank
ROA 0.86%
ROE 2%
ROCE 4.53%
ROIC 3.58%
ROICexc 3.87%
ROICexgc 18.77%
OM 6.96%
PM (TTM) 1.51%
GM 62.4%
FCFM 15.23%
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
ROICexc(3y)2.32%
ROICexc(5y)2.16%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.66%
ROCE(5y)2.18%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y111.19%
ROICexc growth 5Y22.93%
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
F-Score6
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF 4.41
Debt/EBITDA 3.81
Cap/Depr 15.35%
Cap/Sales 1.55%
Interest Coverage 250
Cash Conversion 98.31%
Profit Quality 1009.48%
Current Ratio 1.94
Quick Ratio 1.45
Altman-Z 1.36
F-Score6
WACC10.5%
ROIC/WACC0.34
Cap/Depr(3y)13.3%
Cap/Depr(5y)13.77%
Cap/Sales(3y)1.71%
Cap/Sales(5y)1.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-87.4%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%351.94%
EPS Next Y3244.14%
EPS Next 2Y354.08%
EPS Next 3Y247.51%
EPS Next 5YN/A
Revenue 1Y (TTM)4.12%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%3.64%
Revenue Next Year4.19%
Revenue Next 2Y4.8%
Revenue Next 3Y4.11%
Revenue Next 5YN/A
EBIT growth 1Y-4.88%
EBIT growth 3Y55.19%
EBIT growth 5Y17.63%
EBIT Next Year193.28%
EBIT Next 3Y47.61%
EBIT Next 5YN/A
FCF growth 1Y-7.43%
FCF growth 3Y6.74%
FCF growth 5Y10.67%
OCF growth 1Y-5.11%
OCF growth 3Y6.07%
OCF growth 5Y11.64%

MESA LABORATORIES INC / MLAB Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MESA LABORATORIES INC?

ChartMill assigns a fundamental rating of 5 / 10 to MLAB.


What is the valuation status of MESA LABORATORIES INC (MLAB) stock?

ChartMill assigns a valuation rating of 6 / 10 to MESA LABORATORIES INC (MLAB). This can be considered as Fairly Valued.


How profitable is MESA LABORATORIES INC (MLAB) stock?

MESA LABORATORIES INC (MLAB) has a profitability rating of 7 / 10.


What is the financial health of MESA LABORATORIES INC (MLAB) stock?

The financial health rating of MESA LABORATORIES INC (MLAB) is 3 / 10.


Can you provide the expected EPS growth for MLAB stock?

The Earnings per Share (EPS) of MESA LABORATORIES INC (MLAB) is expected to grow by 3244.14% in the next year.